We have shown that the combined targeting of CD44 and FAK, using anti-CD44 and the clinical-grade FAK inhibitor defactinib, inhibits the adhesion of the most primitive AML cells that are associated with drug resistance and disease relapse. This evidence concerns the gene PTK2 and acute myeloid leukemia.